Cellectar Announces 1-for-10 Reverse Stock Split
July 13, 2018 16:05 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., July 13, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for Treatment of Ewing’s Sarcoma
July 09, 2018 08:00 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., July 09, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
Cellectar Announces Expansion of Diffuse Large B-Cell Lymphoma Cohort in CLR 131 Phase 2 Trial
June 28, 2018 08:00 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., June 28, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Cellectar Granted U.S. Patent for the Treatment of Various Cancers and Cancer Stem Cells with CLR 131
June 07, 2018 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., June 07, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Rhabdomyosarcoma
June 06, 2018 08:00 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., June 06, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
Cellectar Reports Recent Corporate Highlights and 2018 First Quarter Financial Results
May 11, 2018 08:00 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., May 11, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
Cellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma
May 09, 2018 14:28 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., May 09, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
Cellectar Receives Rare Pediatric Disease Designation for CLR 131 to Treat Neuroblastoma
May 02, 2018 08:00 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., May 02, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
Cellectar Presents Preclinical Data at AACR Annual Meeting Demonstrating Efficacy of Fractionated Injections of CLR 131 in Multiple Myeloma
April 17, 2018 08:00 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., April 17, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
Cellectar Presents Preclinical Data at AACR Annual Meeting Demonstrating the Ability of its PDCs to Selectively Target a Broad Range of Tumor Cells
April 16, 2018 08:05 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., April 16, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...